FRA
HALO icon

Front Row Advisors’s Halozyme HALO Stock Holding History

Front Row Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-139
Closed -$7.28K – 650
2024
Q2 		$7.28K Sell
139
-20
-13% -$877 ﹤0.01% 650
2024
Q1 		$6.47K Buy
+159
New +$5.96K ﹤0.01% 680
2023
Q4 		– Sell
-134
Closed -$5.12K – 614
2023
Q3 		$5.12K Hold
134
– – ﹤0.01% 665
2023
Q2 		$5K Hold
134
– – ﹤0.01% 665
2023
Q1 		$5K Buy
134
+34
+34% +$1.59K ﹤0.01% 667
2022
Q4 		$6K Buy
100
+19
+23% +$973 ﹤0.01% 608
2022
Q3 		$3K Buy
+81
New +$3.58K ﹤0.01% 751

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Front Row Advisors's HALO Position: Q3 2024 in Review

Front Row Advisors sold out of Halozyme (HALO) in Q3 2024, closing a stake of 139 shares — an estimated $7.28K sold.

Front Row Advisors first reported a position in HALO in Q3 2022 and held it in 7 quarters. The position peaked at $7.28K in Q2 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q3 2024.

  • Front Row Advisors reported no remaining Halozyme position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 139 Halozyme shares in Q3 2024, an estimated $7.28K.
  • Front Row Advisors first reported a position in Halozyme in Q3 2022 and held it in 7 quarters.
  • Front Row Advisors's Halozyme position peaked at $7.28K in Q2 2024.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.